Rationale: A molecular test to distinguish between sepsis and systemic inflammation of noninfectious etiology could potentially have clinical utility.
Sepsis is a common and potentially lethal medical condition for which treatment is time sensitive. Distinguishing between sepsis and noninfectious systemic inflammatory response syndrome (SIRS) is clinically challenging, especially early in the course of illness when no site of infection or pathogen has been identified and when organ damage has not yet become evident. Uncertainty in diagnosis can lead to delays in therapy or unnecessary use of antibiotics.
Cultures from blood and other body fluids are commonly ordered to identify a source or a pathogen but require at least 12 hours of incubation and are often either negative or inconclusive when positive for nonpathogenic organisms.
Molecular methods have increasingly been investigated as tools for diagnosing sepsis. Authors of several recent publications (1-10) have proposed diagnostic criteria for discriminating sepsis from SIRS on the basis of combinations of molecular (RNA or protein) biomarkers. Advantages of molecular testing for diagnosing sepsis include improved sensitivity and specificity beyond that provided by clinical or biochemical variables, as well as early detection of organ dysfunction.
Using a definition of sepsis as SIRS criteria plus infection (without requiring overt organ dysfunction), we previously reported the discovery and validation of SeptiCyte LAB (Immunexpress Inc.), a signature based on whole-blood expression levels of four genes (CEACAM4, LAMP1, PLAC8, PLA2G7) involved in the host response to infection (4, 7) . SeptiCyte LAB is the first host response gene expression assay cleared by the U.S. Food and Drug Administration (FDA) for diagnosis of sepsis [510(k) premarket notification K163260 (11)]. SeptiCyte LAB was able to discriminate between SIRS and sepsis with an area under the receiver operating characteristic curve of 0.82-0.89, and it provided a probability of infection. In this paper, we report on the clinical performance of SeptiCyte LAB in a clinical trial involving 447 patients. We found that the test result (SeptiScore) directly correlates with the probability of sepsis, suggesting that the SeptiScore, especially when combined with commonly used demographic, clinical, or laboratory variables, could serve as a tool to aid clinicians in distinguishing sepsis from SIRS. Some of the results of this study were previously reported in the form of abstracts (12, 13) .
Methods Clinical Sites
This paper combines the results of three separate prospective, observational studies to achieve an evaluation of the clinical performance of SeptiCyte LAB. The first study involved the testing and analysis of 198 subjects from a much larger consortium trial, the MARS (Molecular Diagnosis and Risk Stratification of Sepsis) trial, which enrolled 7,500 patients at the Academic Medical Center (AMC) Amsterdam critical care patients, either as a stand-alone test or in combination with other clinical variables and laboratory assessments used to confirm or exclude a diagnosis of sepsis. A "sepsis event" was defined operationally to have occurred when a patient displayed two or more signs of systemic inflammation and was given therapeutic systemic antibiotics by the attending clinician within 24 hours of ICU admission.
Adult critical care patients aged 18-89 years were considered qualified for enrollment if, upon admission to an ICU, they displayed two or more of the following signs: temperature above 38 8 C or less than 36 8 C, heart rate greater than 90 beats per minute, tachypnea greater than 20 breaths per minute or Pa CO 2 less than 32 mm Hg, and white blood cell (WBC) count greater than 12,000/mm 3 or less than 4,000/mm 3 or greater than 10% immature neutrophils (bands).
Patients were excluded if 1) clinical cultures or serologic tests were not obtained when sepsis was suspected, 2) they were admitted to ICU more than 24 hours before trial enrollment, 3) they had a delay of more than 24 hours between trial enrollment and sample draw, 4) they underwent elective cardiac surgery with an expected ICU length of stay less than 24 hours, 5) they were treated with antibiotics more than 24 hours before ICU admission for any reason other than surgical prophylaxis (VENUS and Venus Supplement only), or 6) they had a documented sepsis event that occurred more than 3 days before ICU admission or more than 2 days after ICU admission (MARS only). Exclusion criteria 5 and 6 were used to exclude patients who had experienced prior sepsis events. Additional details on study recruitment and patient exclusions are given in the online supplement, part 1.
Laboratory Procedures
SeptiCyte LAB. SeptiCyte LAB used a 2.5-ml sample of whole blood collected by venipuncture into a PAXgene Blood RNA Tube (catalog number 762165, FDA 510k number K042613; BD Biosciences) within 24 hours of admission to the ICU. Experiments in which increasing dilutions of WBC were spiked into leukocyte-depleted blood and assayed established that the limit of detection of SeptiCyte LAB was 270 WBC per cubic millimeter of whole blood (11) . Therefore, a subject's WBC count was required be at least 270 per cubic millimeter of whole blood to be successfully tested with SeptiCyte LAB. PAXgene tubes were handled per the manufacturer's instructions and stored at less than or equal to 270 8 C until tested. Total RNA was isolated using the PAXgene Blood RNA Kit (catalog number 762164; Qiagen). Purified total RNA was required to have 2-50 ng/ml concentration (by A 260 measurement) and adequate purity (as estimated by A 260 /A 280 ratio >1.6). RNA was tested immediately after extraction or stored frozen in single-use portions at less than or equal to 270 8 C until tested. SeptiCyte LAB is a real-time RT-qPCR assay that quantitates the relative expression levels of four genes (CEACAM4, LAMP1, PLAC8, PLA2G7) (4, 7). The format of the assay used in the present study was a boxed kit with turnaround time (from sample draw to report) of approximately 6 hours. The assay was performed on an Applied Biosystems 7500 Fast Dx RealTime PCR instrument (Thermo Fisher Scientific) with kits provided to each site. Testing was performed in CLIA (Clinical Laboratory Improvement Amendments)-certified laboratories at Asuragen (Austin, TX), Providence Medical Center (Portland, OR), and Intermountain Medical Center (Murray, UT). All testing with SeptiCyte LAB was conducted on banked specimens. SeptiCyte LAB test results were not provided to the study investigators or clinicians.
SeptiCyte LAB generates a quantitative score (SeptiScore) falling into one of four ranges (bands) defined as follows: band 1 (0.0 < SeptiScore < 3.0), band 2 (3.1 < SeptiScore < 4.4), band 3 (4.5 < SeptiScore < 5.9), and band 4 (6.0 < SeptiScore < 10.0). The fractions of sepsis and SIRS subjects falling into each SeptiScore band, and the resultant sepsis/SIRS likelihood ratios, were calculated as described in the online supplement, part 2. For the goal of diagnosing sepsis, a SeptiScore value of 3.1 was operationally defined as a binary cutoff, with values greater than or equal to 3.1 considered to provide evidence for infection and values of 3.0 or less considered to provide evidence for noninfection. The cutoff of 3.1 had been preset on the basis of an entirely independent, nonoverlapping discovery dataset (4).
Procalcitonin. Procalcitonin (PCT) assays were performed at Providence Medical Center (Portland, OR) using a commercially available kit (VIDAS B.R.A.H.M.S PCT; bioMérieux). PCT concentrations greater than 2 mg/ml were considered to indicate a high risk of severe sepsis and/or septic shock, as per the VIDAS B.R.A.H.M.S PCT 510k Decision Summary (K071146).
Reference Method
Patient classification (sepsis, SIRS, or indeterminate) by an external threemember expert panel was used as the reference method (14) and is described fully in the online supplement, part 3. Some diagnostic discordance was expected, even for an expert panel, and especially for certain subpopulations (e.g., sepsis originating from pneumonia). Three different retrospective physician diagnosis (RPD) algorithms were used. Diagnosis was designated "consensus" if two panelists agreed (first algorithm; n = 180 sepsis, 230 SIRS, 37 indeterminate) or "unanimous" if all three panelists agreed with each other and with the consensus discharge evaluation of the site investigators at the hospital in question (second algorithm; n = 119 sepsis, 171 SIRS). If the panelists all disagreed, or if all deemed a subject indeterminate, then the diagnosis was considered indeterminate (37 of 447 [8.3%] ). In the third RPD algorithm ("forced" approach), indeterminates underwent a second blinded independent case review and were forced into either the sepsis or SIRS category (n = 202 sepsis, 245 SIRS). The forced algorithm, by requiring a binary judgment (sepsis or SIRS) to be made about each indeterminate subject, was expected to result in some wrong classifications and therefore to produce a lower bound estimate of SeptiCyte LAB performance.
Data Analysis
Performance relative to the three reference algorithms (unanimous, consensus, forced RPD) using receiver operating characteristic (ROC) curve analyses and calculation of area under the curve (AUC) (15) was performed using the R package pROC (16) unless otherwise noted. Comparison of AUCs between correlated ROC curves was performed using DeLong's method (17) . Single-variable and multivariable analyses were used to determine which variables were most predictive of sepsis versus SIRS. Four different multivariate analysis methods were used: 1) forward logistic regression with directed variable selection, 2) logistic regression with random variable selection, 3) ridge/lasso regression, and 4) random decision forests. The following 14 variables were examined by themselves and were also included in modeling: SeptiScore, PCT, maximum glucose concentration, minimum white blood cell count, maximum white blood cell count, maximum mean arterial pressure, minimum core temperature, maximum core temperature, minimum heart rate, maximum heart rate, number of SIRS criteria, age, sex, and race/ethnicity. Details are provided in the online supplement, parts 4-6.
Reporting
This article was composed according to the Standards for Reporting Diagnostic Accuracy (18) . Descriptions of MARS and VENUS have been uploaded to www.clinicaltrials.gov under the identifiers NCT01905033 and NCT02127502, respectively.
Results
The complete clinical dataset consisted of 447 adult critical care patients from three different studies (Figure 1) Clinical and laboratory characteristics for all patients are described in Table 2 . Septic patients were sicker overall, with a longer length of ICU stay and total duration of hospitalization than those with SIRS or with indeterminate classifications. Common clinical variables used in SIRS criteria displayed small but significant differences between the SIRS and sepsis groups (P values in Table 2) .
SeptiScore values were significantly higher in septic patients (Table 2) , and ROC curve analysis produced AUC values of 0.89, 0.85, and 0.82 for unanimous, consensus, and forced RPD, respectively (Figure 2A ). For the binary discrimination of sepsis versus SIRS in our dataset, the relationship between cut point, sensitivity, and specificity (derived from the ROC curve) is shown in Figure 2B . We used the SeptiScore value 3.1, previously chosen from an independent clinical dataset (4), as a binary cutoff. Values of 3.1 or greater provided evidence for sepsis, and values less than 3.1 provided evidence for SIRS. This choice of cutoff is biased toward sensitivity at the expense of specificity and was made because of asymmetry in the patient risk profile: a false-negative call (in which sepsis is missed and antibiotics potentially withheld) has greater deleterious consequence than a false-positive call (in which there is no systemic infection and antibiotics potentially given unnecessarily). Using a cutoff of 3.1, the sensitivity of SeptiScore for identifying septic patients was greatest for unanimous RPD cases (0.97) compared with consensus (0.94) or forced RPD (0.92); negative predictive values were 0.89 or greater (Table 3) .
When SeptiScores were organized into numerical bands (band 1, 0-3.0; band 2, 3.1-4.4; band 3, 4.5-5.9; band 4, 6-10), a positive correlation between band number and probability of sepsis was observed (Figure 3) . Unanimous sepsis patients more frequently had SeptiScore levels within bands 3 and 4 (86.0%) than patients with SIRS (29.8%) ( Figure 3A) . A similar distribution of sepsis by consensus and by forced classification was observed for each SeptiScore band, with 83.3% of consensus septic patients and 80.2% of forced sepsis classification falling within bands 3 and 4 ( Figures 3B and 3C, respectively) . Four patients (3.3%) unanimously determined to have sepsis had a SeptiScore within band 1 and did not have positive blood cultures. Sixty-nine patients with consensus RPD diagnoses of SIRS (30.0% of all patients with SIRS) had SeptiScores falling in bands 3 or 4. Heterogeneity within this subgroup is indicated by detailed analysis of clinical parameters (online supplement, part 7), with some patients showing clinical characteristics consistent with systemic infection or sepsis. SeptiScores were randomly distributed across the four bands for indeterminate cases. For blood culture-positive cases that were not suspected of contamination, no SeptiScores fell in band 1 (assay sensitivity, 1.00; 95% confidence interval, 0.93-1.00), and SeptiScores were heavily skewed toward bands 3 and 4. Additional information about the distribution of indeterminate and blood culture-positive subjects across SeptiScore bands is provided in the online supplement, part 7.
We excluded subjects who received therapeutic antibiotics before ICU admission, and we reevaluated SeptiCyte LAB performance. The original set of 447 subjects gave an AUC of 0.852 with consensus RPD as the comparator. After removing 139 subjects who had received therapeutic antibiotics before ICU admission, the remaining set of 308 subjects gave an AUC of 0.848. DeLong's test (17) for comparison of two ROC curves was performed, which demonstrated that there was no significant difference between the two ROC curves (D = 0.108, df = 569.54, P = 0.914).
We evaluated SeptiCyte LAB in comparison to or in combination with other demographic, clinical, and laboratory variables, as well as with assessments available within the first 24 hours of ICU admission, for discriminating SIRS from sepsis. For these comparisons, the combined . We stratified the data into the three separate cohorts (MARS, VENUS, VENUS Supplement), also by race/ethnicity or sex, Definition of abbreviations: AUC = area under the curve; NPV = negative predictive value; PI = principal investigator; PPV = positive predictive value; RPD = retrospective physician diagnosis; SIRS = systemic inflammatory response syndrome. A SeptiCyte LAB cutoff value of 3.1 was used in the analysis. This value had been obtained previously from receiver operating curve analysis of an independent discovery dataset (4). and also by identified site of infection, without a significant effect on SeptiCyte LAB performance (online supplement, part 5). We next used forward logistic regression to combine variables in order of decreasing relative univariate contribution. The results from the forward logistic regression were in general agreement with three other multivariate analysis methods: logistic regression with random variable selection, ridge/lasso regression, and random decision forests. In all multivariate analyses, combining SeptiScore with clinical signs and laboratory variables, including PCT, did not significantly improve the overall performance of SeptiCyte LAB compared with its use alone (Figure 4 ). Taking this analysis further, Figure 5 presents the results from a complete permutation analysis of all 14 variables, resulting in 16,383 independent logistic models, using only complete datasets without missing values imputed (comparator = consensus RPD). Other methods of imputing missing values, and other methods of combining variables, were tested with essentially the same results (online supplement, part 6). In all analyses, adding SeptiScore as a variable significantly improved the discrimination of sepsis versus SIRS relative to classifiers without SeptiScore.
Discussion
Differential diagnosis of sepsis and SIRS continues to be a diagnostic challenge of practical importance (19) (20) (21) (22) . We report findings from a prospective, multicenter clinical evaluation of SeptiCyte LAB, an FDA-cleared and previously described fourgene host expression classifier designed to distinguish sepsis from SIRS in adult patients on the first day of ICU admission (4). Our primary objective was to establish the performance characteristics of SeptiScore in a study with a racially and ethnically diverse patient population of 447 subjects from seven clinical sites in the United States and one clinical site in the Netherlands. We determined the AUC of SeptiCyte LAB to range from 0.82 to 0.89, depending on the degree of confidence in the clinical diagnosis. SeptiCyte LAB had the highest AUC when the clinical RPD was unanimous (0.89) and lowest with forced RPD (0.82). These two reference methods may thus represent upper and lower bounds, respectively, on SeptiCyte LAB performance independent of other clinical data. Performance characteristics in this study are similar to those of our previous discovery and validation cohorts, which were more racially homogeneous (mostly white) (4). Similar performance levels were observed for SeptiCyte LAB, regardless of stratification by study cohort/geographic origin (MARS vs. VENUS vs. VENUS Supplement), by race/ethnicity or sex, or by site of identified infection (online supplement, part 5).
Our secondary objective was to determine how SeptiCyte LAB performance compared with other clinical signs and laboratory variables often used to diagnose sepsis (including PCT) available within 24 hours of ICU admission. Individually, SeptiCyte LAB appeared to outperform these other variables (online supplement, part 4). Combining clinical variables with SeptiScores led to marginal increases in AUC score with or without inclusion of PCT. Performance of the multivariable predictor models varied on the basis of clinical confidence of the reference method. As expected, the highest AUCs were observed with the unanimous RPD and lowest with the forced RPD. We note that the FDA-cleared intended use of SeptiCyte LAB differs from and is complementary to that of PCT. The latter test is cleared for predicting progression from severe sepsis to septic shock, for predicting 28-day mortality, and for managing antibiotic de-escalation. Our study included ICU patients who fulfilled at least two SIRS criteria. Our sepsis cohort presented with typically diverse sources of sepsis, with pneumonia being the most common infection site. SeptiCyte LAB had the highest AUC and SeptiScores in patients with bloodstream infection. In contrast, SeptiCyte LAB, as with other sepsis biomarkers (23, 24) , appeared to perform less well in patients with pneumonia. Another challenging subgroup consisted of patients who had undergone mechanical ventilation. Difficulties in assessing these two overlapping patient subgroups may be due to inherent challenges in diagnosing pneumonia, particularly in ventilated patients (25, 26) . In our study, this was indicated by relatively low values of interobserver concordance (Cohen's kappa values for concordance between RPD panelists fell to 0.2-0.4 for pneumonia patients and 0.6 for ventilated patients, respectively). Of note, low interobserver concordance in the comparator method will lead to high apparent misclassification rates by the index test and thus to underestimation of the true performance of the index test relative to ground truth. With sufficiently low interobserver concordance, differences in apparent performance may be explained by this effect.
We believe our study offers a number of strengths. First, our population likely represents the diversity of patients with sepsis in ICUs encountered at most hospitals, because the study included patients from multiple geographical locations and medical facilities (online supplement, part 1). Second, patient status (sepsis, SIRS, or indeterminate) was assessed by three different methods (unanimous, consensus, or forced RPD). The best (unanimous) and worst (forced) scenarios establish the lower and upper performance bounds, respectively, for SeptiCyte LAB. To our knowledge, this approach to establishing performance bounds has not been described previously. Third, we applied a novel diagnostic method (host response gene expression assay) to a complex clinical problem.
Our study has several important limitations. First, we defined sepsis as SIRS criteria plus infection (without requiring overt organ dysfunction). Although this definition is sensitive to early septic events, it is not a perfect definition and could potentially miss cases of sepsis that occur in the absence of systemic inflammation (27) . Second, the consensus RPD process was unable to assign a definitive classification to 8.3% (37 of 447) of patients (indeterminates). Thus, we bracketed the performance estimates by use of unanimous RPD (upper performance bound; many samples rejected) and forced RPD (lower performance bound; no samples rejected). Actual performance of SeptiCyte LAB (with consensus RPD as the comparator) likely will fall between these two bounds.
Third, a significant fraction of subjects (273 of 447 [61%]) had gaps in the clinical data record used in the multivariate analysis, as detailed in Table E13 of the online supplement, part 6. There was significant variability between sites with respect to the completeness of capture of clinical data in case report forms. To partially address the limitation, we conducted the multivariate analyses in two ways: 1) using only those patients with complete clinical data; and 2) using all patients, with imputation of the missing data values by various methods. Combining SeptiScore with other clinical variables (including or excluding PCT) did not significantly improve the performance of SeptiCyte LAB compared with its use alone, regardless of analysis method or exclusion or imputation of missing values.
Fourth, multivariate analysis may introduce or fail to limit bias. The RPD panelists considered all available clinical information in making their assessments, including the values of some of the variables used in the multivariate analysis (detailed in the online supplement, part 3). Thus, we would expect some correlation between the RPDs and the multivariate analysis results. The magnitude of such a correlation cannot be measured under our . Area under the curve (AUC) distributions for logistic models. An exhaustive examination of all 16,383 possible logistic combinations of the following 14 variables was conducted: SeptiScore, procalcitonin, maximum glucose concentration, minimum white blood cell count, maximum white blood cell count, maximum mean arterial pressure, minimum core temperature, maximum core temperature, minimum heart rate, maximum heart rate, number of systemic inflammatory response syndrome criteria, age, sex, and race/ethnicity. No imputation of missing values was performed. The comparator was consensus retrospective physician diagnosis. Blue = models containing SeptiScore; green = models containing procalcitonin but not SeptiScore; red = models without SeptiScore or procalcitonin.
study design but would be expected to produce overestimates of AUC performance. We found in the multivariate analysis that little gain in AUC performance was produced by serial addition of variables, suggesting either that this type of bias was present or that the variables are truly not uniquely informative. Regardless, the test is not designed to be run independently of clinical variables or clinical judgment. Fifth, SeptiCyte LAB relies solely on host response characteristics, whereas the ideal sepsis biomarker strategy may require a combination of host response and direct pathogen detection (28) (29) (30) (31) (32) 
